Abstract

Gonadotropin releasing hormone (GnRH) analogues are now marketed in the UK for the treatment of patients with endometriosis. Endometriosis is an oestrogen-dependent disorder, and conventional medical treatments have relied on mechanisms that oppose the effects of oestrogen, e.g. an androgen (danazol) or a progestagen (norethisterone). GnRH analogues work by suppressing oestrogen secretion.